Last 7 days
-2.8%
Last 30 days
-3.7%
Last 90 days
-6.6%
Trailing 12 Months
-18.6%
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
JNJ | 443.8B | 96.0B | -4.81% | 2.94% | 23.17 | 4.62 | 5.02% | 7.14% |
LLY | 313.5B | 29.2B | -4.62% | 48.31% | 51.95 | 10.72 | 5.34% | 1.02% |
MRK | 270.7B | 59.0B | -4.68% | 39.38% | 17.74 | 4.59 | 27.84% | 112.03% |
PFE | 248.1B | 99.9B | -13.46% | -13.81% | 8.33 | 2.48 | 45.01% | 53.21% |
BMY | 155.2B | 46.7B | 0.52% | 19.86% | 23.24 | 3.32 | 2.79% | 223.53% |
MID-CAP | ||||||||
PRGO | 4.9B | 4.4B | 7.51% | -2.25% | -45.96 | 1.12 | 1.80% | 57.67% |
SUPN | 2.2B | 659.0M | 11.94% | 39.90% | 58.05 | 3.32 | 16.78% | -53.92% |
SMALL-CAP | ||||||||
TLRY | 1.8B | 613.6M | 16.73% | -44.78% | -3.63 | 3.01 | 37.73% | -7.19% |
RETA | 1.5B | 3.1M | 20.50% | 54.60% | -4.79 | 474.09 | -77.09% | -12.24% |
CGC | 1.3B | - | 32.06% | -61.83% | -0.44 | 1.95 | -4.11% | -144.36% |
ACRS | 1.1B | 23.5M | 11.91% | 62.20% | -13.66 | 47.73 | 243.57% | -1.04% |
CRON | 919.4M | 112.7M | -2.41% | -28.74% | -4.11 | 8.16 | 45.53% | 40.26% |
INVA | 884.8M | - | -3.72% | -18.56% | 2.65 | 2.34 | 10.49% | -16.07% |
OCUL | 299.6M | 49.7M | 47.35% | -29.01% | -5.05 | 6.02 | 28.95% | 32.80% |
ENDP | 94.1M | 2.6B | -43.99% | -88.43% | -0.03 | 0.04 | -13.88% | -4855.92% |
Income Statement (Last 12 Months) | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q3 | 2022Q2 | 2021Q4 | 2021Q3 | 2021Q2 |
Revenue | NaN% | null | null | 392 | 375 | 365 |
Operating Expenses | -144.6% | -59.81 | 134 | 17 | -9.32 | - |
S&GA Expenses | 102.9% | 49 | 24 | 16 | 19 | - |
R&D Expenses | 55.8% | 31 | 20 | 1 | 1 | - |
EBITDA | 60.1% | 441 | 275 | 478 | - | - |
EBITDA Margin | -44.2% | 0.68* | 1.22* | - | - | - |
Earnings Before Taxes | 66.7% | 408 | 245 | 445 | 480 | - |
EBT Margin | -46.6% | 0.61* | 1.14* | - | - | - |
Interest Expenses | 1.9% | 17 | 16 | 19 | 19 | - |
Net Income | 61.1% | 334 | 208 | 369 | 398 | - |
Net Income Margin | -45.4% | 0.51* | 0.94* | - | - | - |
Free Cahsflow | -21.8% | 291 | 372 | 364 | - | - |
Balance Sheet | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 |
Assets | 16.7% | 1,328 | 1,138 | 1,107 | 926 | 887 |
Current Assets | 13.6% | 455 | 400 | 318 | 314 | 237 |
Cash Equivalents | 6.1% | 301 | 284 | 217 | 202 | 135 |
Inventory | Infinity% | 71 | - | - | - | - |
Net PPE | -6.2% | 0 | 0 | 0 | 0 | 0 |
Goodwill | 188.6% | 16 | 6 | 6 | - | - |
Current Liabilities | 30.2% | 164 | 126 | 109 | 6 | 3 |
LT Debt, Non Current | 0.1% | 444 | 443 | 443 | 395 | 392 |
Shareholder's Equity | 13.4% | 641 | 565 | 552 | 415 | 492 |
Retained Earnings | 66.0% | -136.60 | -402.20 | -403.14 | -456.15 | -466.49 |
Additional Paid-In Capital | -1.1% | 1,171 | 1,184 | 1,183 | 1,264 | 1,262 |
Shares Outstanding | 0.1% | 70 | 70 | 70 | 70 | 69 |
Minority Interest | -100.0% | - | 177 | 166 | 111 | 89 |
Cashflow (Last 12 Months) | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 |
Cashflow From Operations | -21.8% | 291 | 372 | 378 | 364 | 351 |
Share Based Compensation | 93.4% | 7 | 3 | 3 | 2 | 2 |
Cashflow From Investing | 59.0% | -67.86 | -165.58 | -73.04 | 44 | -251.85 |
Cashflow From Financing | -271.2% | -57.63 | 34 | -370.86 | -452.50 | -442.94 |
Dividend Payments | - | 0 | - | - | - | - |
Buy Backs | NaN% | 0 | 0 | 394 | 0 | - |
66.2%
55.8%
35.8%
Y-axis is the maximum loss one would have experienced if Innoviva was unfortunately bought at previous high price.
4.7%
-3.8%
-3.1%
FIve years rolling returns for Innoviva.
Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
2023-01-25 | Lindbrook Capital, LLC | reduced | -90.03 | -9,715 | 1,285 | -% |
2023-01-25 | GRIMES & COMPANY, INC. | reduced | -0.9 | 17,526 | 147,526 | 0.01% |
2023-01-25 | WHITTIER TRUST CO | unchanged | - | 818 | 9,818 | -% |
2023-01-24 | Louisiana State Employees Retirement System | reduced | -0.67 | 47,000 | 395,000 | 0.01% |
2023-01-23 | Allspring Global Investments Holdings, LLC | added | 438.68 | 3,007,440 | 3,591,440 | 0.01% |
2023-01-20 | Prairiewood Capital, LLC | reduced | -1.12 | 117,068 | 1,028,070 | 0.76% |
2023-01-20 | Diligent Investors, LLC | sold off | -100 | -134,000 | - | -% |
2023-01-19 | RITHOLTZ WEALTH MANAGEMENT | reduced | -43.66 | -160,633 | 289,367 | 0.02% |
2023-01-18 | Maryland State Retirement & Pension System | new | - | 340,446 | 340,446 | 0.01% |
2023-01-18 | Verition Fund Management LLC | added | 199.88 | 293,000 | 508,000 | -% |
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Jan 20, 2023 | blackrock inc. | 10.6% | 5,671,100 | SC 13G | |
Jul 11, 2022 | vanguard group inc | 10.00% | 6,970,950 | SC 13G/A | |
Feb 11, 2022 | renaissance technologies llc | 7.62% | 5,295,133 | SC 13G/A | |
Feb 01, 2022 | westfield capital management co lp | 5.3% | 3,683,485 | SC 13G | |
Jan 28, 2022 | blackrock inc. | 13.0% | 9,008,758 | SC 13G/A | |
Jun 07, 2021 | renaissance technologies llc | 10.79% | 7,491,342 | SC 13G/A | |
May 25, 2021 | sarissa capital management lp | 9.24% | 6,414,000 | SC 13D/A | |
May 25, 2021 | glaxosmithkline plc | 0% | 0 | SC 13D/A | |
Feb 12, 2021 | glaxosmithkline plc | 31.6% | 32,005,260 | SC 13D/A | |
Feb 11, 2021 | renaissance technologies llc | 7.77% | 7,881,802 | SC 13G/A |
Date Filed | Form Type | Document | |
---|---|---|---|
Jan 20, 2023 | SC 13G | Major Ownership Report | |
Jan 12, 2023 | 4 | Insider Trading | |
Jan 10, 2023 | SC 13D/A | 13D - Major Acquisition | |
Jan 06, 2023 | 3 | Insider Trading | |
Jan 04, 2023 | 8-K | Current Report | |
Nov 22, 2022 | 4 | Insider Trading | |
Nov 09, 2022 | 8-K | Current Report | |
Nov 09, 2022 | 10-Q | Quarterly Report | |
Oct 28, 2022 | 8-K/A | Current Report |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
2022-11-18 | Zhen Marianne | sold (taxes) | -11,219.4 | 13.55 | -828 | chief accounting officer |
2022-11-15 | Zhen Marianne | acquired | - | - | 433 | chief accounting officer |
2022-08-19 | Zhen Marianne | sold (taxes) | -11,719.6 | 14.12 | -830 | chief accounting officer |
2022-05-20 | Zhen Marianne | sold (taxes) | -13,488.1 | 16.29 | -828 | chief accounting officer |
2022-05-13 | Zhen Marianne | acquired | - | - | 1,834 | chief accounting officer |
2022-04-25 | Haimovitz Jules | acquired | - | - | 12,647 | - |
2022-04-25 | Birx Deborah | acquired | - | - | 12,647 | - |
2022-04-25 | Odysseas Kostas D | acquired | - | - | 12,647 | - |
2022-04-25 | DiPaolo Mark | acquired | - | - | 12,647 | - |
2022-04-25 | Schlesinger Sarah J. | acquired | - | - | 12,647 | - |
CONDENSED CONSOLIDATED STATEMENTS OF INCOME - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | 9 Months Ended | ||
---|---|---|---|---|
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
Revenue: | ||||
Total revenue | $ 67,257 | $ 97,862 | $ 265,536 | $ 284,186 |
Expenses: | ||||
Selling, general and administrative | 27,810 | 2,860 | 46,084 | 13,074 |
Research and development | 11,725 | 449 | 31,447 | 536 |
Amortization of intangible assets | 1,511 | 0 | 1,511 | 0 |
Gain on sale of Theravance Respiratory Company, LLC ("TRC") | (266,696) | 0 | (266,696) | 0 |
Loss on extinguishment of debt | 0 | 0 | 20,662 | 0 |
Changes in fair values of equity and long-term investments, net | (130) | (33,613) | 67,881 | (133,973) |
Interest and dividend income | (2,135) | (453) | (3,181) | (503) |
Interest expense | 5,096 | 4,790 | 11,761 | 14,229 |
Other expense (income), net | (28) | 652 | 750 | 2,036 |
Total expenses | (219,167) | (25,315) | (86,101) | (104,601) |
Income before income taxes | 286,424 | 123,177 | 351,637 | 388,787 |
Income tax expense net | 57,077 | 20,531 | 63,061 | 65,600 |
Net income (loss) | 229,347 | 102,646 | 288,576 | 323,187 |
Net income (loss) attributable to noncontrolling interests | (36,176) | 30,208 | 6,341 | 67,678 |
Net income attributable to Innoviva stockholders | $ 265,523 | $ 72,438 | $ 282,235 | $ 255,509 |
Basic net income per share attributable to Innoviva stockholders | $ 3.81 | $ 1.04 | $ 4.05 | $ 2.96 |
Diluted net income per share attributable to Innoviva stockholders | $ 2.80 | $ 0.90 | $ 3.07 | $ 2.63 |
Shares used to compute Innoviva basic and diluted net income per share: | ||||
Shares used to compute basic net income per share | 69,731 | 69,458 | 69,640 | 86,298 |
Shares used to compute diluted net income per share | 95,830 | 81,699 | 95,072 | 98,536 |
Royalty revenue from a related party | ||||
Revenue: | ||||
Total revenue | $ 62,150 | $ 97,862 | $ 260,429 | $ 284,186 |
Net product sales | ||||
Revenue: | ||||
Total revenue | 5,107 | 0 | 5,107 | 0 |
Expenses: | ||||
Cost of products sold (inclusive of amortization of inventory fair value adjustments, excluding depreciation and amortization of intangible assets) | $ 3,680 | $ 0 | $ 3,680 | $ 0 |
CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands | Sep. 30, 2022 | Dec. 31, 2021 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 300,789 | $ 201,525 |
Short-term marketable securities | 282 | 0 |
Accounts receivable | 6,743 | 0 |
Receivables from collaboration arrangement | 65,606 | 110,711 |
Inventory | 70,807 | 0 |
Prepaid expenses | 7,932 | 1,367 |
Other current assets | 2,432 | 70 |
Total current assets | 454,591 | 313,673 |
Property and equipment, net | 165 | 12 |
Equity and long-term investments | 489,111 | 483,845 |
Capitalized fees paid to a related party, net | 101,062 | 111,430 |
Right-of-use assets | 3,679 | 97 |
Goodwill | 15,995 | 0 |
Intangible assets | 258,489 | 0 |
Deferred tax assets, net | 0 | 17,327 |
Other assets | 4,620 | 11 |
Total assets | 1,327,712 | 926,395 |
Current liabilities: | ||
Accounts payable | 3,805 | 27 |
Accrued personnel-related expenses | 6,473 | 619 |
Accrued interest payable | 5,702 | 4,152 |
Deferred revenue | 2,849 | 0 |
Convertible subordinated notes due 2023, net of issuance costs | 96,131 | 0 |
Income tax payable | 33,804 | 0 |
Other accrued liabilities | 15,120 | 1,009 |
Total current liabilities | 163,884 | 5,807 |
Long-term debt, net of discount and issuance costs | 443,679 | 394,653 |
Other long-term liabilities | 78,421 | 0 |
Deferred tax liabilities | 360 | 0 |
Commitments and contingencies (Note 11) | ||
Stockholders' equity: | ||
Preferred stock: $0.01 par value, 230 shares authorized, no shares issued and outstanding | 0 | 0 |
Common stock: $0.01 par value, 200,000 shares authorized, 69,776 and 69,566 issued and outstanding as of September 30, 2022 and December 31, 2021 respectively | 698 | 696 |
Treasury stock: at cost, 32,005 shares as of September 30, 2022 and December 31, 2021, respectively | (393,829) | (393,829) |
Additional paid-in capital | 1,171,096 | 1,264,024 |
Accumulated deficit | (136,597) | (456,148) |
Total Innoviva stockholders' equity | 641,368 | 414,743 |
Noncontrolling interest | 0 | 111,192 |
Total stockholders' equity | 641,368 | 525,935 |
Total liabilities and stockholders' equity | $ 1,327,712 | $ 926,395 |